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Metachromatic leukodystrophy (MLD) is a lysosomal 
storage disease caused by a functional deficiency of the 
lysosomal enzyme arylsulfatase A. The prevailing late-
infantile variant of MLD is characterized by widespread 
and progressive demyelination of the central nervous 
system (CNS) causing death during childhood. In order 
to gain insight into the pathomechanism of the disease 
and to identify novel therapeutic targets, we analyzed 
neuroinflammation in two mouse models reproducing 
a mild, nondemyelinating, and a more severe, demy-
elinating, variant of MLD, respectively. Microgliosis and 
upregulation of cytokine/chemokine levels were clearly 
more pronounced in the demyelinating model. The 
analysis of the temporal cytokine/chemokine profiles 
revealed that the onset of demyelination is preceded by 
a sustained elevation of the macrophage inflammatory 
protein (MIP)-1α followed by an upregulation of MIP-
1β, monocyte chemotactic protein (MCP)-1, and several 
interleukins. The tumor necrosis factor (TNF)-α remains 
unchanged. Treatment of the demyelinating mouse 
model with the nonsteroidal anti-inflammatory drug 
simvastatin reduced neuroinflammation, improved the 
swimming performance and ataxic gait, and retarded 
demyelination of the spinal cord. Our data suggest that 
neuroinflammation is causative for demyelination in 
MLD mice and that anti-inflammatory treatment might 
be a novel therapeutic option to improve the CNS func-
tion of MLD patients.
Received 23 December 2014; accepted 6 April 2015; advance online  
publication 12 May 2015. doi:10.1038/mt.2015.69
INTRODUCTION
Lysosomal storage diseases (LSDs) are a group of ~50 inherited 
metabolic disorders that result from defects of the lysosomal 
homeostasis leading to the intralysosomal accumulation of unde-
graded macromolecules, a severe multisystemic disease pheno-
type and early death.1 Together, LSDs have an incidence of 1/7,000 
newborns and therefore represent an important subgroup among 
genetic neurological disorders. Different organs such as the liver, 
spleen, bone, cartilage, and/or the nervous system can be affected. 
In approximately two third of the LSDs, the clinical picture is 
dominated by a progressive CNS disease caused by neurodegen-
eration or demyelination. The CNS symptoms vary between LSD 
entities and variants and can involve mental retardation, ataxia, 
seizures, dementia, deafness, and blindness.
In contrast to the diversity in lysosomal storage materials, 
affected cell types, and neurological symptoms, neuroinflam-
mation appears to be a common theme of all LSDs with CNS 
involvement. Microgliosis and elevated levels of cytokines and 
chemokines have been detected in mouse models of mucopolysac-
charidosis (MPS) type I,2,3 MPS IIIA,3 MPS IIIB,2,3 Niemann-Pick 
type C,4 GM1-gangliosidosis,5 Sandhoff disease,5–7 neuronopathic 
Gaucher disease,8 Farber disease,9 globoid cell leukodystrophy,10,11 
and neuronal ceroid lipofuscinosis.12 In some of these models, e.g., 
of Farber disease,13 Sandhoff disease,14 and globoid cell leukodys-
trophy,15 neuroinflammation results in the recruitment of periph-
eral immune cells to the CNS.
Metachromatic leukodystrophy (MLD; OMIM #250100) 
is a LSD caused by a functional deficiency of the lysosomal 
enzyme arylsulfatase A (ASA; E.C. 3.1.6.8). The deficiency 
leads to the intralysosomal accumulation of the sphingolipid 
3-O-sulfogalactosylceramide (sulfatide), demyelination of the 
CNS, severe neurological symptoms, and premature death.16 
Neuroinflammation has not yet been studied in MLD. To fill this 
gap, we made use of two MLD mouse models. Nondemyelinating 
ASA knockout mice develop a mild form of the disease which is 
reminiscent of preclinical stages of MLD.17 The life expectancy is, 
however, not reduced and these mice never show progressive and 
widespread demyelination which is the hallmark of the human 
disease. ASA knockout mice which overexpress a cerebroside sul-
fotransferase transgene from a proteolipoprotein promoter have a 
more severe phenotype.18 This is explained by an increased rate of 
sulfatide synthesis in myelinating cells accelerating sulfatide stor-
age and manifestation of symptoms. The demyelinating model has 
a reduced life span of 18–20 months, starts to demyelinate at age 
16 months and develops severe neurological symptoms including 
hind limb paralysis. It is, therefore, a more authentic model of the 
human condition and considered to recapitulate the clinical phase 
of MLD.
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In the present study, we demonstrate that both mouse mod-
els develop progressive neuroinflammation which correlates with 
the degree of sulfatide storage and severity of neurological symp-
toms. Furthermore, we provide the first in vivo data on an anti-
inflammatory treatment approach for MLD. For this purpose, 
demyelinating MLD mice were fed with simvastatin, a nonsteroi-
dal anti-inflammatory drug which has not been tested in any LSD 
mouse model before.
RESULTS
Design of study
Nondemyelinating and demyelinating MLD mice were studied 
at two ages. First, after the onset of symptoms at 12 months and 
second, preferably late in their disease progression. While, the 
normal life expectancy of nondemyelinating MLD mice allowed 
the second analysis at 24 months, demyelinating MLD mice were 
analyzed at 16–18 months due to the high mortality after the onset 
of myelin loss (at 16 months). For cytokine/chemokine measure-
ments, five mice reaching an exceptional old age of 20 months 
were additionally included. Sulfatide storage of the relevant 
age groups was analyzed by thin layer chromatography (TLC). 
Compared with wild-type controls, mean sulfatide levels of non-
demyelinating MLD mice were increased 1.3- and 1.7-fold at 12 
and 24 months, respectively (Figure 1). For 12- and 17-month-old 
demyelinating MLD mice, the factors of increase were 1.8 and 2.4, 
respectively.
Microgliosis and astrogliosis
The brain and spinal cord of the two MLD mouse models were 
analyzed by immunostaining of histological sections with anti-
bodies to F4/80 and to the glial fibrillary acidic protein, respec-
tively. As shown for the brain stem in Figure 2, staining of the 
microglial marker F4/80 reveals an enlargment of cell somata 
and thickening of cellular processes, two morphological changes 
indicative of reactive microgliosis. In 12-month-old nondemy-
elinating ASA knockout mice, these histological alterations are 
faint and confined to the brain stem, cerebellar white matter, and 
corpus callosum, whereas microglial activation is clearly ampli-
fied and generalized at 24 months as well as in 12-month-old 
demyelinating MLD mice. Microgliosis progresses substantially 
until end-stage disease as shown by the advanced morphological 
changes in 16-month-old demyelinating MLD mice. Microglial 
Figure 1  Sulfatide storage in brains of nondemyelinating (Nondem.) 
and demyelinating metachromatic leukodystrophy mice. Sulfatide of 
the indicated groups of mice was analyzed by TLC. Cholesterol was used 
as an internal standard, and the ratio between sulfatide and cholesterol 
(sulf/chol) was calculated. The normalized sulfatide levels are expressed 
as fold increase above mean levels of wild-type tissues. Bars represent 
means ± SEM (n = 3). Statistically significant differences to wild-type 
controls are indicated by asterisks (*P < 0.05).
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Figure 2 Microgliosis and astrogliosis in the two metachromatic 
 leukodystrophy mouse models. Sagittal brain sections of n = 2–3 mice 
per group were stained with antibodies to the microglial marker protein 
F4/80 (left panel) and the astroglial marker protein glial fibrillary acidic 
protein (right panel), respectively. Nuclei were counterstained with 
4′,6-diamidino-2-phenylindole. Representative immunofluorescence 
stainings of corresponding regions of the brain stem (medulla oblon-
gata) are shown. Groups and ages as indicated on the left of the images. 
Inserts are higher power images of individual microglial and astroglial 
cells, respectively. Bars represent 50 µm (overviews) and 25 µm (inserts), 
respectively.
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activation is paralleled by progressive astrogliosis in both ani-
mal models as indicated by an increasing number of glial fibril-
lary acidic protein-positive cells and the enlargement of radiating 
astrocytic processes particularly in the corpus callosum and other 
white matter tracts.
Cytokine/chemokine profiles
Cytokines/chemokines were quantified by enzyme-linked 
immunosorbent assay (ELISA) on whole brain homogenates. 
For nondemyelinating ASA knockout mice, the levels of inter-
leukin (IL)-1β, keratinocyte chemoattractant (KC, CXCL1) and 
macrophage inflammatory protein (MIP)-1α (CCL3) were ana-
lyzed at age 12 and 24 months. Compared to wild-type controls, 
the only increase was found for MIP-1α at 24 months (Figure 3). 
Similar investigations with single-plex ELISAs revealed more 
complex changes of cytokines/chemokines in the demyelinating 
MLD mouse model (not shown). To obtain detailed information 
about the temporal cytokine/chemokine profile in these mice, 
23 factors implicated in neuroinflammatory pathways were 
quantified by multi-plex ELISAs at age 10, 16, and 20 months. 
In contrast to the nondemyelinating model, overexpression 
of MIP-1α was detectable at 10 months and persisted until 20 
months (Figure 4). The increase of other factors was temporally 
delayed. Monocyte chemotactic proteins (MCP)-1 (CCL2) and 
MIP-1β (CCL4), for example, were elevated only at 16 and 20 
months. First increases of KC and RANTES (CCL5) occurred 
even later and were detectable at 20 months for the first time. 
A stage-dependent upregulation was also seen for a variety of 
interleukins with a transient increase of IL-1β, IL-9, IL-13, IL-17 
at 16 months and sustained overexpression of IL-6 and IL-12 
p40 at 16 and 20 months. During the course of the disease, the 
Figure 3 Brain cytokine/chemokine levels of nondemyelinating 
metachromatic leukodystrophy (MLD) mice. The concentration of 
the indicated factors was determined in ASA knockout mice (closed 
bars) and age-matched wild-type controls (open bars) at age (a) 12 and 
(b) 24 months, respectively. Cytokines levels were quantified by single-
plex enzyme-linked immunosorbent assays, normalized to the protein 
concentration of the homogenate and expressed as multiples of the 
mean wild-type levels. The bars represent means ± SEM of n = 3 mice 
per group. Asterisks indicate statistically significant differences between 
MLD mice and controls (*P < 0.05).
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Figure 4 Brain cytokine/chemokine levels of demyelinating meta-
chromatic leukodystrophy (MLD) mice. The concentration of the 
indicated 23 factors was determined in MLD mice (closed bars) and 
age-matched wild-type controls (open bars) at age (a) 10, (b) 16, 
and (c) 20 months, respectively. Cytokines/chemokines were quanti-
fied by multi-plex enzyme-linked immunosorbent assay, normalized 
to the  protein concentration of the corresponding homogenate and 
expressed as multiples of the mean wild-type levels. The bars represent 
means ± SEM of n = 3–5 mice per group. Asterisks indicate statistically 
significant differences between MLD mice and controls (*P < 0.05). nd, 
not determinable.
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overexpression was highest for IL-9 (4.9-fold), MCP-1 (4.2-fold) 
and MIP-1α (3.2-fold).
Infiltration of immune cells into the CNS
The function of MIP-1α, MIP-1β, and MCP-1 involves the che-
moattraction of peripheral immune cells to sites of inflammation. 
Due to the upregulation of these factors, a possible infiltration of 
granulocytes, T-cells, and monocytes into the brain was inves-
tigated by immunostaining of brain sections of 17-month-old 
demyelinating MLD mice for cell type–specific marker proteins 
(Figure 5a). Staining of granulocytes with anti Ly-6G antibod-
ies revealed prominent signals in spleen sections, stained as 
a control, but no signals in brain sections of MLD mice. Anti 
CD3ε antibodies, on the contrary, detected T-cells in the brains 
of demyelinating MLD mice. Immunoreactivity was specifically 
found in the vicinity of blood vessels, but not within the brain 
parenchyma indicating a perivascular localization of the infil-
trated T-cells. Staining was absent from age-matched wild-type 
controls. Staining of the surface protein F4/80 and counterstain-
ing of cell nuclei with 4′,6-diamidino-2-phenylindole allowed for 
the detection of cell somata of microglial cells and macrophages. 
Quantification of such somata in two brain regions (medulla 
oblongata, medial cerebellar nucleus) of wild-type controls and 
demyelinating MLD mice revealed no significant changes in 
the number of microglia/macrophages (shown for the medulla 
oblongata in Figure 5b).
Anti-inflammatory therapy
Demyelinating MLD mice were treated with 20 mg/kg/day sim-
vastatin for 30 days. Simvastatin was tolerated by all age groups 
without any obvious side effects. TLC revealed no alterations of 
sulfatide and cholesterol levels in the CNS (not shown). Effects 
of treatment on microgliosis and behavioral deficits were ana-
lyzed in 12-month-old mice (13 months at the end of treatment). 
Simvastatin reduced the microgliosis (Figure 6a, upper panel), 
prevented or reversed infiltration of T-cells into the CNS (Figure 
6a, lower panel) and normalized the elevated brain levels of 
MIP-1α (Figure 6b). The swimming performance, gait pattern, 
and elevated plus maze behavior are sensitive measures of neu-
rological symptoms associated with ASA deficiency in mice. To 
detect the effects of treatment on behavioral deficits, simvastatin-
treated MLD mice were compared with mock-treated MLD mice 
and wild-type controls. During exploration of the elevated plus 
maze, MLD mice spent relatively more time in the open arms 
than controls, independent of treatment (Figure 6c; F = 14, P < 
0.001). In swim tests, mock-treated MLD mice swam signifi-
cantly slower than control mice and simvastatin treatment did not 
increase swimming velocity (Figure 6d; F = 69, P < 0.001). Some 
mice needed to be rescued from the water before the end of the 
trial when showing difficulties to continue swimming (F = 6.1, 
P < 0.01). Notably, mock-treated MLD mice completed a signifi-
cantly lower percentage of the swim trial in comparison with con-
trol mice (P < 0.01) and simvastatin-treated MLD mice (P < 0.05) 
(Figure 6e). Hence, simvastatin significantly increased the swim-
ming endurance. Treadmill analyses confirmed earlier findings of 
gait disturbances by showing significantly elevated incongruity 
coefficients for front/hind and left/right stride lengths in mock-
treated MLD mice (Figure 6f) (F = 3.4 and 3.7; both P < 0.05). 
Both coefficients were reduced to wild-type levels in simvastatin-
treated MLD mice (P < 0.05 and P = 0.07 versus mock-treated 
MLD mice), demonstrating normalization of the ataxic gait under 
these testing conditions.
To investigate therapeutic effects on myelin maintenance, 
MLD mice were treated from 17 months onwards, i.e., 1 month 
after the onset of demyelination. Behavioral tests were not fea-
sible at that advanced age due to the progressed motor handicaps 
Figure 5 Infiltration of peripheral immune cells into the brain of demy-
elinating metachromatic leukodystrophy (MLD) mice. (a) Sagittal 
sections through the medial cerebellar nucleus of 17-month-old demy-
elinating MLD mice and wild-type controls were immunostained with 
antibodies to the granulocyte marker protein Ly-6G (upper panel; insert 
shows spleen section as positive control) and the pan T-cell marker protein 
CD3ε (lower panel; insert shows perivascular T-cells under higher mag-
nification), respectively. Nuclei were counterstained with 4′,6-diamidino-
2-phenylindole. Representative immunofluorescence images of n = 2–3 
mice per group are shown. Bars represent 50 µm (overviews), 100 µm 
(insert, granulocytes), and 25 µm (insert, T-cells) respectively. The gran-
ule cell layer is indicated by asterisks. (b) Macrophages/microglial cells in 
the medulla oblongata of the indicated groups of mice. F4/80-positive 
nucleated profiles were counted as described in the method section. 
No significant differences between groups were detectable. Bars are 
means ± SEM of n = 2–3 mice per group.
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precluding gait and swim tests. Quantification of myelin basic 
protein (MBP) in total brain of mock-treated MLD mice at the 
end of the treatment period (18 months) revealed a significant 
drop of the myelin content to 58% of the wild-type level (Figure 
7a). In simvastatin-treated mice, 20% more MBP than in mock-
treated controls was detectable on average. This increase was 
not significant. In the spinal cord, MBP was reduced to 45% of 
the wild-type level on average (Figure 7b). Contrary to brain, 
simvastatin caused a significant increase of the MBP level by 
58% in this tissue. These results were confirmed for 1 month 
younger animals in an independent experiment. Again, simvas-
tatin treatment did not significantly increase the myelin content 
of total brain, whereas 42% more MBP was found in the spinal 
cord (P < 0.05; not shown). Consequently, the myelin loss in the 
spinal cord was reduced by roughly one half in both trials. As 
a measure of anti-inflammatory effects of simvastatin, the “key 
chemokines” MIP-1α, MIP-1β, and MCP-1 were quantified in 
17–18-month-old mice. Interestingly, a differential response of 
brain and spinal cord to simvastatin was detectable. While none 
Figure 6 Therapeutic effects of simvastatin treatment on histologi-
cal, biochemical, and behavioral measures of demyelinating meta-
chromatic leukodystrophy (MLD) mice treated from months 12 
to 13. (a) Immunostaining of brain sections through the brain stem 
(medulla oblongata) with antibodies to Iba-1 (upper panel) and CD3ε 
(lower panel) in mock- and simvastatin-treated mice as indicated. Nuclei 
were counterstained with 4′,6-diamidino-2-phenylindole. Representative 
immunofluorescence images of n = 3 mice per group are shown. Iba-1 
staining is reduced and T-cell infiltration reversed in simvastatin-treated 
mice compared to mock-treated controls. (b) MIP-1α was quantified 
by enzyme-linked immunosorbent assay in total brain homogenates of 
13-month-old wild-type mice (wt), mock-treated MLD mice (mock), 
and simvastatin-treated MLD mice (simva). Bars represent means ± SEM. 
(c) Elevated plus maze behavior. (d) Swimming velocity. (e) Completion 
of the swim trial as a measure of swimming endurance. (f) Incongruity 
coefficients as measures of gait uniformity in wild-type controls (open 
bars), mock-treated MLD mice (closed bars), and simvastatin-treated 
MLD mice (hatched bars). FS-HS, front to hind stride length; LS-RS, left 
to right stride length (for a description of these parameters see ref. 37. Bars 
represent means ± SEM of (b) n = 3 and (c–f) n = 16–21 mice per group, 
respectively. Statistically significant differences to wild-type controls are 
indicated by asterisks (*P < 0.05; **P < 0.01; ***P < 0.001). Significant 
therapeutic effects are highlighted by plus-signs (+P < 0.05).
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Figure 7 Therapeutic effects of simvastatin treatment on myelin 
maintenance and cytokine/chemokine expression in the CNS of 
demyelinating metachromatic leukodystrophy (MLD) mice treated 
beyond age 16 months. Bars represent means ± SEM of n = 3–4 mice 
per group. (a,b) MBP levels in (a) total brain and (b) spinal cord of wild-
type controls (wt), mock-treated MLD-mice (mock), and simvastatin-
treated MLD mice (simva) treated from months 17 to 18. Asterisks and 
plus-signs indicate statistically significant differences as described in the 
legend to Figure 6. (c,d) MIP-1α, MIP-1β, and MCP-1 in (c) brain and 
(d) spinal cord of simvastatin-treated mice (hatched bars) and mock-
treated controls (closed bars) treated from months 16 to 17. To show the 
treatment-mediated decline of the chemokines, the concentrations are 
expressed as pg per mg protein and normalized on the concentrations 
measured in mock-treated MLD mice. Asterisks indicate statistically sig-
nificant differences between mock- and simvastatin-treated MLD mice 
(*P < 0.05). Note that a significant decline of chemokines (MCP-1, MIP-
1β) and a significant increase of MBP levels is detectable in the spinal 
cord (b,d), but not in the brain (a,c).
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of the three factors was significantly diminished in total brain 
(Figure 7c), a significant decline of MCP-1α and MIP-1β was 
detectable in spinal cord (Figure 7d).
DISCUSSION
Nondemyelinating and demyelinating MLD mice develop histolog-
ical characteristics of reactive microglia, with enlarged cell bodies 
and thicker processes (Figure 2).19 These morphological changes 
progress with advancing sulfatide storage (Figure 1) and correlate 
with disease severity. The examination of cell numbers did, however, 
not provide evidence that proliferation, a common consequence of 
microglial activation, contributes to the enlargement of the microg-
lial compartment seen in Figure 2 (Figure 5b). It is tempting to 
speculate that the absence of proliferation is due to lysosulfatide, a 
derivative of sulfatide and secondary storage product in MLD mice 
and patients, as it inhibits cell division of cultured cells by signal-
ling through TDAG8, a G-protein bound receptor that is mainly 
expressed by cells of the monocyte/macrophage lineage.16,20
In accordance with glial activation, a number of cytokines/
chemokines were found to be upregulated in the brains of demye-
linating MLD mice (Figure 4). The temporal cytokine/chemokine 
profile is highly complex and characterized by a transient peak of 
several factors at the onset of demyelination at 16 months and a 
decline thereafter. Interestingly, several neuroinflammatory mark-
ers that are upregulated in twitcher mice (an animal model of the 
related LSD globoid cell leukodystrophy), show similar kinetics 
with only transient maxima in the beginning of the demyelination 
process.15,21 Why and how the factors are downregulated in spite 
of ongoing myelin breakdown during end-stage disease requires 
further investigation. Pathohistological features of reactive micro-
gliosis are prominent in postmortem material from MLD patients 
as well. Data on cytokines/chemokines have, however, not been 
published to date.16 It is therefore not possible to relate the cyto-
kine/chemokine profiles of MLD mice with patient data.
MIP-1α is among the factors with the highest levels in the clini-
cal phase and the only factor that is elevated in preclinical stages 
(Figures 3 and 4). Early and high overexpression of MIP-1α has 
been detected in many mouse models of LSDs with neuroinflamma-
tion.3,4,6,7,8,10,11 The factor is a proinflammatory chemokine that can 
be expressed by activated microglial cells.22,23 Its functions involve 
the recruitment of immune cells and the activation of target cells 
to release proinflammatory mediators. The latter may explain the 
delayed upregulation of MIP-1β, MCP-1, and several interleukins 
in MLD mice. The redundant functions of MIP-1α, MIP-1β, and 
MCP-1 in cell recruitment prompted studies on the infiltration of 
peripheral immune cells into the CNS of the animals. Morphometric 
studies provided no evidence for the infiltration of peripheral mono-
cytes into the brain parenchyma, a salient feature of globoid cell 
leukodystrophy (Figure 5b). In twitcher mice, infiltration starts 
around postnatal day 30, i.e., 10 days after the onset of demyelin-
ation.15 The delay was explained by the phagocytic activity of brain-
resident microglial cells being sufficient to clear myelin debris in the 
beginning of the demyelination process. However, once the need 
of phagocytotic activity extends beyond the capacity of the local 
microglia, additional phagocytes are recruited from the periphery. 
This model might explain the obvious lack of monocyte infiltration 
into the brain of MLD mice, as demyelination never reaches the 
extent seen in twitcher mice. T-cells, on the contrary, do infiltrate the 
CNS (Figure 5a), an observation that has also been made in twitcher 
mice.15 The T-cell subtypes and the consequences of the T-cell infil-
tration are still unknown necessitating further investigations.
It is important to mention that the classical acute pro-inflam-
matory cytokine TNF-α is not elevated in MLD mice at any stage 
(Figure 4). Also, the IFN-γ concentration shows only a transient 
and negligible increase by less than 20%. Both factors are impli-
cated in the activation of signaling pathways leading to the upreg-
ulation of other cytokines/chemokines and believed to induce an 
acute inflammatory event which eventually “matures” into chronic 
inflammation. Thus, early and sustained elevation of TNF-α is a 
hallmark of Alzheimer’s disease, Parkinson’s disease, and multi-
ple sclerosis in humans as well as several LSDs in mouse models, 
such as neuronopathic Gaucher disease, GM1-gangliosidosis, and 
Sandhoff disease.5,8,24,25 Consequently, the neuroinflammatory cas-
cade of these diseases appears to be different from that of MLD. 
Notably, also in twitcher mice, TNF-α and IFN-γ seem to play no 
major role in neuroinflammation.11,26
To address the question whether neuroinflammation is favor-
able or detrimental for the disease progression in MLD, we used 
a pharmacological approach and treated mice with the anti-
inflammatory drug simvastatin. This drug was chosen because it 
is the most potent statin in crossing the blood–brain barrier and 
inhibits the MAPK signal transduction pathway through which 
MIP-1α, MIP-1β, and MCP-1 signal.27,28 Oral treatment of demy-
elinating MLD mice caused a significant reduction of neuroin-
flammation in the CNS as shown by a partial normalization of 
the microglial cell morphology, the reversal of T-cell infiltration 
and the drop of elevated cytokine/chemokines levels (Figures 6 
and 7). Interestingly, MIP-1α declined significantly only in early 
treated mice (12–13 months; Figure 6b), but not at a later stage 
(16–17 months; Figure 7c) suggesting that this factor might reach 
a “point of no return” after the onset of demyelination.
The most important result of the study is that simvastatin 
has the potential to delay or even halt the demyelination process 
in the CNS. This was shown for the spinal cord of demyelinating 
MLD mice treated shortly after the onset of demyelination where 
the loss of myelin could be reduced by roughly 50% (Figure 7). 
Remarkably, simvastatin had no significant effect on the demy-
elination of the brain. This may suggest that the parenchyma of 
the spinal cord acquires higher drug concentrations than the brain 
parenchyma. This notion is supported by the observation that 
MIP-1β and MCP-1 levels in spinal cord, but not in brain could be 
significantly reduced by simvastatin treatment. Notably, the atten-
uation of neuroinflammation in 12–13-month-old mice was paral-
leled by improvements of the swimming endurance and ataxic gait 
(Figure 6). It should be noted, however, that swimming velocity 
was still severely reduced and that gait was evaluated at a low speed, 
as MLD mice could not achieve higher pace at a consistent level. 
Furthermore, signs of blunted affect in the elevated plus maze did 
not respond to simvastatin treatment. The general picture reflects 
enhanced motor behavior but persistent problems with coordi-
nated movement and emotional functions in simvastatin-treated 
animals. This profile is consistent with the observations that lower 
brain regions and spinal cord acquired more benefit from treat-
ment. It could be speculated that more global CNS effects might be 
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achieved by longer treatment with higher simvastatin doses and/or 
intracerebroventricular administration of the drug.
The beneficial effect of treatment on histological, biochemical, 
and behavioral measures is in accordance with data from mouse 
models of other LSDs in which the nonsteroidal anti-inflamma-
tory drugs aspirin, ibuprofen, and indomethacin slowed the rate 
of disease progression.29–31 Neuroinflammation, therefore, appears 
to be a critical and deleterious factor in the pathomechanism of 
MLD and other LSDs rather than a secondary response to an 
otherwise inflammation-independent disease process. Figure 8 
shows a pathomechanistic model for MLD mice that is based on 
the effectiveness of anti-inflammatory treatment and the chronol-
ogy of events in the disease progression. The model is supported 
by the observation that sulfatide per se elicits morphological alter-
ations and upregulation of inflammatory mediators when added 
to the culture medium of primary rat microglial cells.32 In how far 
this model is applicable to MLD patients is still to be investigated, 
as clinical data about neuroinflammation and anti-inflammatory 
treatment are lacking. The scheme illustrates that the relation-
ship between cell type-specific storage accumulation, neuroin-
flammation, cell loss and neurological symptoms is likely to be 
highly complex. The relative contribution of storage and inflam-
mation to pathology, particularly demyelination, is an important 
issue that has to be addressed by future studies comparing anti- 
inflammatory treatment, enzyme replacement therapy, and com-
binations between the two treatment modalities. Such studies are 
also demanded by the observation that combination therapies that 
target the primary enzyme defect by CNS-directed gene therapy 
or enzyme replacement therapy (ERT) and neuroinflammation, as 
a secondary pathogenic mechanism, resulted in additive or even 
synergistic therapeutic effects in other LSD mouse models.33
From a clinical perspective, our results may suggest that anti-
inflammatory treatment is a new therapeutic option for MLD 
patients. For a first clinical trial, young children with the late-infan-
tile form of MLD would probably be adequate candidates as they 
show a relatively uniform clinical course that can be quantified 
using MLD-specific clinical scoring systems.34,35 Such patients are 
usually diagnosed between 18 and 24 months of age due to motor 
coordination problems that may be reflected by the gait distur-
bances seen in demyelinating MLD mice around age 12 months.34 
Similar to MLD mice younger than 16 months, 86% of patients 
display, however, only mild signs of CNS demyelination before 
their third birthday.35 This cross-species correlation suggests a 
therapeutic window between diagnosis and myelin breakdown of 
at least one year in which treatment may be initiated to possibly 
prevent or postpone irreversible CNS damages. Simvastatin is a 
standard drug for hypercholesterinemia and under investigation 
in clinical trials for multiple sclerosis, Alzheimer’s disease, and 
other CNS disorders.36 The biodynamics and safety profiles are, 
therefore, well known such that a transfer into clinical practice 
might be relatively straightforward.
MATERIALS AND METHODS
Mice. ASA knockout mice, a nondemyelinating animal model of MLD, have 
been constructed by homologous recombination in embryonic stem cells.17 
A more severe, demyelinating mouse model, has been generated by intro-
ducing a cerebroside sulfotransferase transgene into the ASA knockout 
Figure 8 Scheme showing the hypothetical relationships between 
sulfatide storage, neuroinflammation, and the CNS disease of 
metachromatic leukodystrophy (MLD) mice. The model is adapted 
from the “vicious cycle” model proposed for sphingolipidoses by 
Jeyakumar et al.5 Deficiency of ASA causes sulfatide storage in oligo-
dendrocytes and, to a lower extent, in astrocytes and subpopulations 
of neurons.39 We hypothesize that lysosomal storage induces stress 
responses leading to an increased rate of oligodendroglial apopto-
sis which, in an early stage of the disease, can be compensated by 
remyelination of the demyelinated lesions. The inhomogeneous 
myelin thickness and increased frequency of hypomyelinated axons 
observed in the CNS of MLD mice are likely to reflect this increased 
rate of myelin repair.18 Phagocytic clearance of the oligodendroglial cell 
debris results in the progressive accumulation of sulfatide in microglial 
cells eventually causing metabolic stress and microgliosis. Astrogliosis, 
elicited by astroglial storage and/or microgliosis, might contribute to 
the progressing neuroinflammatory process. Above a certain concen-
tration, cytokines/chemokines (and possibly other inflammatory fac-
tors) secreted by the activated glial cells may become cytotoxic and 
induce widespread apoptosis of oligodendrocytes that are predisposed 
to damage by massive sulfatide storage. The loss of oligodendrocytes 
causes demyelination which extent exceeds the remyelination capacity 
of the CNS and further amplifies neuroinflammation via the redistri-
bution of undegradable sulfatide to the microglia. While the severe 
neurological manifestations seen in end-stage disease are dominated 
by the rapid loss of myelin, neuronal dysfunctions induced by sulfatide 
storage and neuroinflammation may determine the pathology before 
the onset of demyelination. A reduction of the cytokine/chemokine 
levels by anti-inflammatory therapy may decelerate the neuroinflam-
matory circuit and thereby reduce the severity of disease.
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background.18 Genotyping was done by polymerase chain reaction on 
genomic mouse tail DNA using primer pairs specific for the wild-type 
and disrupted murine ASA allele and the cerebroside sulfotransferase- 
transgene, respectively. Wild-type control mice were age- and strain-
matched to the MLD mice. Mice were kept in groups on a 12-hour-light 
and 12-hour-dark schedule in accordance with the current German law on 
the protection of animals.
Treatment. Mice were orally treated with 20 mg/kg simvastatin (Absource 
Diagnostics GmbH, Munich, Germany) per day for 30 days. For this pur-
pose, regular mouse food was powdered and supplemented with 1.08 mg/g 
simvastatin. Each day, mice received 0.5 g Simvastatin-supplemented pow-
der food per 27 g body weight (average weight of experimental animals). 
To warrant complete oral uptake of the drug, mice were kept with access 
to water, but without food from 6:00 p.m. to 8:00 a.m. (14 hours). Then, 
the fasted mice were placed into solitary cages harboring a 35-mm Petri 
dish with the simvastatin-supplemented powder food. After complete 
consumption (usually within 30 minutes), mice were put back into their 
normal cages with ad libitum access to their regular diet and water. Control 
mice obtained powdered food without simvastatin according to the same 
schedule. No significant drop of the body weight or other side effects 
were detectable during the treatment period in any experimental group 
(not shown). All animal experiments were approved by the state office for 
nature, environment, and consumer protection of North-Rhine Westfalia, 
Germany (LANUV NRW reference number 84-02.04.2011.A180).
Behavioral studies. Mice were analyzed by behavioral tests in the third 
week of treatment. Three experimental groups were compared: wild-type 
controls (n = 21) and demyelinating MLD mice receiving either mock- 
or simvastatin-treatment (both n = 16). For the determination of swim-
ming parameters, mice were placed at the same starting point in a circular 
pool (diameter 150 cm), filled with water (26 °C). Swimming paths were 
recorded for 30 seconds using the EthoVision video tracking equipment 
(Noldus Bv, Wageningen, The Netherlands). Mice which were unable to 
complete the swim trial were removed from the pool before they became 
at risk of drowning. The percentage of test completion was recorded as a 
measure of swimming endurance. Gait patterns were analyzed while mice 
were ventrally video-tracked on a transparent treadmill belt (Digigait, 
MouseSpecifics, MA), basically as described.37 Following brief habitua-
tion to the apparatus, mice were tested at a constant belt speed of 10 cm/
seconds. This low speed was chosen as MLD mice had difficulties to keep 
pace with the treadmill at higher speeds, prohibiting quantified gait analy-
sis. Different parameters were extracted from the video data using Digigait 
analysis software, such as base-widths (distance between contralateral 
paws) and stride lengths (distance between subsequent placements of 
the same paw). Subsequently, incongruity coefficients were calculated as 
a measure of gait uniformity. These coefficients are defined as the abso-
lute value of the difference between the standard scores or z-scores for 
the subject on two concurrent parameters. Dissimilar deviations of the 
group mean for the parameters will result in a higher score for incongru-
ity. Exploration in the elevated plus maze was measured as an index of 
emotional function. Mice could freely explore the test arena for 10 min-
utes, which consisted of a plus-shaped maze with two arms (5 cm wide) 
closed by side walls and two arms without walls. An IR beam recording the 
percentage of time per minute spent in the open arms was connected to a 
computerized activity logger.
Histological, biochemical, and morphometric investigations. After 
the 30th treatment, mice were deeply anesthetized, transcardially per-
fused with phosphate-buffered saline pH 7.4, and relevant tissues were 
dissected out and snap-frozen on a block of dry ice.37 Cryosections (10 
µm) were prepared as described38 and incubated with rat anti-F4/80 
antibody (1:100, kindly provided by D. Hartmann, Bonn), rabbit anti-
Iba1 antibody (1:200, Wako Chemicals, Germany), rabbit anti-CD3ε 
antibody (1:100, New England BioLabs, Ipswich), or mouse anti-glial 
fibrillary acidic protein antibody (2A5) (1:200, Abcam, Cambridge, 
UK) as primary antibodies. Secondary antibodies were Cy3-conjugated 
goat anti-rabbit, goat anti-rat, and goat anti-mouse IgG, respectively 
(each 1:200; Dianova, Hamburg, Germany). For biochemical analyses, 
tissues were homogenized in Tris-buffered saline pH 7.4 containing 
Complete protease inhibitor cocktail (Roche, Mannheim, Germany). 
Homogenates were centrifuged 10 minutes at 10,000 × g, and protein 
concentrations of the supernatants were measured using the Bio-Rad 
Dc assay (Bio-Rad, Munich, Germany). For western blotting, identical 
amounts (20 µg) of total protein were separated by 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis and transferred onto nitrocel-
lulose membranes (Whatman, Dassel, Germany) by semi-dry blotting. 
Bound proteins were detected with a mixture of rabbit anti-MBP anti-
body AB980 (1:2,000, Merck Millipore, Darmstadt, Germany) and either 
mouse anti-α-tubulin antibody B-5-1-2 or mouse anti-β-actin  antibody 
AC-74 (both 1:1,000, Sigma-Aldrich, St. Louis, MO). Secondary 
antibodies were IRD-680-conjugated goat anti-rabbit and IRD- 
800-conjugated goat anti-mouse IgG antibody (each 1:10,000; Dianova, 
Hamburg, Germany). Membranes were scanned on an Odyssey infra-
red imager (Li-Cor, Lincoln) and signals were quantified using the 
Odyssey Software V3.0.21. Cytokines/chemokines were quantified by 
ELISA. A bead-based multiplex sandwich immunoassay kit (Bio-Plex 
Pro Mouse Cytokine 23-plex Panel, Bio-Rad) allowed the quantifica-
tion of the following 23 cytokines/chemokines in parallel: IL-1α, IL-1β, 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, 
IL-17, eotaxin, granulocyte colony-stimulating factor, granulocyte-
macrophage colony-stimulating factor, interferon (IFN) γ, keratinocyte 
chemoattractant (KC), macrophage chemoattractant protein (MCP)-
1, macrophage-inflammatory protein (MIP)-1α, MIP-1β, RANTES, 
and tumor necrosis factor (TNF)-α. For multiplex ELISAs, tissue 
homogenates were diluted 1:2 in Bio-Plex Cell Lysis Buffer (Bio-Rad 
Laboratories, Hercules, CA) containing Complete protease inhibitor 
cocktail, frozen and thawed, sonicated for 10 seconds, and centrifuged 
at 10,000 × g for 10 minutes. The supernatants, containing protein con-
centrations of 3–4 mg/ml, were diluted 1:3 in Bio-Plex sample diluent 
and used for the multiplex assay according to the manufacturer’s recom-
mendations. The beads were analyzed on a Bio-Plex 200 system (Bio-
Rad). In some experiments, MIP-1α and other cytokines/chemokines 
were quantified by traditional plate-based single-plex ELISAs accord-
ing to the recommendations of the manufacturer (Peprotech, Hamburg, 
Germany). Lipids were extracted from tissue homogenates and analyzed 
by TLC as previously described.38 The combined number of microglial 
cells and macrophages was evaluated by morphometric analysis using 
brain cryosections stained with antibodies to F4/80 and counterstained 
with 4′,6-diamidino-2-phenylindole. The number of F4/80-positive cell 
somata harboring a cell nucleus was counted by visual inspection in 
test areas (425 × 330 µm each) of three parallel sagittal sections through 
corresponding regions of the medulla oblongata and medial cerebellar 
nucleus of n = 3 mice per group. The values were used for the calculation 
of arithmetic means and SEMs of experimental groups.
Statistics. For the evaluation of biochemical data, statistical analysis was 
done by unpaired Student’s t-test using InStat version 3.06 (GraphPad, San 
Diego, CA). P < 0.05 was considered statistically significant. For behavioral 
tests, group comparisons were carried out using analysis of variance proce-
dures with Fisher least significant difference tests for post hoc analysis. The 
significance threshold was set at α = 0.05.
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